Detection of novel diagnostic antibodies in ankylosing spondylitis: An overview

详细信息    查看全文

• 作者：Dana H.F. Quaden¹ ; Liesbeth M. De Winter¹ ; Veerle Somers ; ^{veerle.somers@uhasselt.be" class="auth_mail" title="E-mail the corresponding author}
• 关键词：Ankylosing spondylitis ; Axial spondyloarthritis ; Antibodies ; Biomarker ; Phage display
• 刊名：Autoimmunity Reviews
• 出版年：2016
• 出版时间：August 2016
• 年：2016
• 卷：15
• 期：8
• 页码：820-832
• 全文大小：758 K

文摘

Ankylosing spondylitis (AS) is a debilitating, chronic, rheumatic disease characterized by inflammation and new bone formation resulting in fusion of the spine and sacroiliac joints. Since early treatment is impeded by a delayed diagnosis, it is highly important to find new biomarkers that improve early diagnosis and may also contribute to a better assessment of disease activity, prognosis and therapy response in AS. Because of the absence of rheumatoid factor, AS was long assumed to have a seronegative character and antibodies are thus not considered a hallmark of the disease. However, emerging evidence suggests plasma cells and autoantibodies to be involved in the disease course. In this review, the role of B cells and antibodies in AS is discussed. Furthermore, an overview is provided of antibodies identified in AS up till now, and their diagnostic potential. Many of these antibody responses were based on small study populations and further validation is lacking. Moreover, most were identified by a hypothesis-driven approach and thus limited to antibodies against targets that are already known to be involved in AS pathogenesis. Hence, we propose an unbiased approach to identify novel diagnostic antibodies. The already successfully applied techniques cDNA phage display and serological antigen selection will be used to identify antibodies against both known and new antigen targets in AS plasma. These newly identified antibodies will enhance early diagnosis of AS and provide more insight into the underlying disease pathology, resulting in a more effective treatment strategy and eventually an improved disease outcome.